logo-loader
GeoVax Labs

GeoVax Labs developing a therapy that potentially cures Hepatitis B

GeoVax Labs Inc. (OTCQB:GOVX) Chairman & CEO David Dodd sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

The clinical-stage biotechnology company is developing human vaccines against infectious diseases using its Modified Vaccinia Ankara - Virus-Like Particle (MVA-VLP) vaccine platform.

Quick facts: GeoVax Labs

Price: $0.04

Market: OTCQB
Market Cap: $106.84 k
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Great Bear Resources releases more positive drill results...

Great Bear Resources (CVE: GBR) President and CEO Chris Taylor joined Steve Darling from Proactive Vancouver to discuss their latest assay results from the drill program on the Dixie Project in Red Lake.  Taylor discusser the results from the Hinge and Dixie Limb zones and also gave...

16 hours, 38 minutes ago

2 min read